Drawing upon our team’s earlier explorations into the formation of PVTT, we postulate that key proteins significantly upregulated in liver cancer, and potentially implicated in PVTT genesis, may play pivotal roles in the progression of HCC following monoclonal antibody therapy targeting PD-L1 and VEGFα. Here, VEGFA is linked to liver cancer.